Madero-Marroquin Rafael, Hunter Ryan W, Saygin Caner, Johnston Hannah, DuVall Adam S, Rahmani Youshanlouei Hamed, Osei Clinton, Shah Syed, Stock Wendy, Gurbuxani Sandeep, Patel Anand A
Department of Medicine, Section of Hematology/Oncology University of Chicago Chicago Illinois USA.
Department of Pathology University of Chicago Chicago Illinois USA.
EJHaem. 2024 Dec 28;6(1):e1076. doi: 10.1002/jha2.1076. eCollection 2025 Feb.
CD58 loss has been described as a mechanism of resistance to blinatumomab and chimeric antigen receptor T-cell therapy, functioning as a modulator of response to T-cell activation.
Using flow cytometry, we evaluated the impact of CD58 mean fluorescence intensity (MFI) on the probability of achieving measurable residual disease (MRD) negativity in patients with B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin (InO).
The odds ratio of achieving MRD negativity was 1.03 for every 1000 unit increase in CD58 MFI.
Our results suggest that MRD negativity rates after InO are high, regardless of the intensity of CD58 expression.
CD58缺失被描述为对贝林妥欧单抗和嵌合抗原受体T细胞疗法产生耐药的一种机制，其作为T细胞活化反应的调节剂发挥作用。
我们采用流式细胞术评估了CD58平均荧光强度（MFI）对接受奥英妥珠单抗（InO）治疗的B细胞急性淋巴细胞白血病患者实现微小残留病（MRD）阴性的概率的影响。
CD58 MFI每增加1000单位，实现MRD阴性的优势比为1.03。
我们的结果表明，无论CD58表达强度如何，InO治疗后的MRD阴性率都很高。
